Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Annals of Surgical Oncology
Published in: Annals of Surgical Oncology 7/2014

01-07-2014 | Endocrine Tumors

Thyroidectomy as Primary Treatment Optimizes Body Mass Index in Patients with Hyperthyroidism

Authors: David F. Schneider, MD, MS, Ratnam Nookala, MBBS, Taylor J. Jaraczewski, Herbert Chen, MD, Carmen C. Solorzano, MD, Rebecca S. Sippel, MD

Published in: Annals of Surgical Oncology | Issue 7/2014

Login to get access

Abstract

Objective

The purpose of this study was to determine how the timing of thyroidectomy influenced postoperative weight change.

Methods

We conducted a two-institution study, identifying patients treated with total thyroidectomy for hyperthyroidism. Patients were classified as ‘early’ if they were referred for surgery as the first treatment option, or ‘delayed’ if they were previously treated with radioactive iodine (RAI). Groups were compared with the Student’s t-test or χ 2 test where appropriate.

Results

There were 204 patients undergoing thyroidectomy for hyperthyroidism. Of these, 171 patients were classified as early and 33 were classified as delayed. Overall, patients gained 6.0 % ±0.8 of their preoperative body weight at last follow-up. Preoperative body mass indexes (BMIs) were similar between groups (p = 0.98), and the median follow-up time was 388 days (range 15–1,584 days). Both groups gained weight until they achieved a normal thyroid-stimulating hormone (TSH) postoperatively. After achieving a normal TSH, the early group stabilized or lost weight (−0.2 lbs/day), while the delayed group continued to gain weight (0.02 lbs/day; p = 0.61). At last follow-up, there were significantly more patients in the delayed group who increased their BMI category compared with the early group (42.4 vs. 21.6 %; p = 0.01). Twice as many patients in the delayed group moved up or into an unhealthy BMI category (overweight or obese) compared with the early group (39.4 vs. 19.3 %; p = 0.01).

Conclusions

Compared with patients initially treated with RAI, patients with hyperthyroidism who underwent surgery as the first treatment were less likely to become overweight or obese postoperatively.
Literature
1.
Schussler-Fiorenza CM, Bruns CM, Chen H. The surgical management of Graves’ disease. J Surg Res. 2006;133(2):207–14.PubMedCrossRef
2.
Jacobsen R, Lundsgaard C, Lorenzen J, Toubro S, Perrild H, Krog-Mikkelsen I, et al. Subnormal energy expenditure: a putative causal factor in the weight gain induced by treatment of hyperthyroidism. Diabetes Obes Metab. 2006;8(2):220–7.PubMedCrossRef
3.
Astrup A, Buemann B, Christensen NJ, Madsen J, Gluud C, Bennett P, et al. The contribution of body composition, substrates, and hormones to the variability in energy expenditure and substrate utilization in premenopausal women. J Clin Endocrinol Metab. 1992;74(2):279–86.PubMed
4.
Toubro S, Sorensen TI, Ronn B, Christensen NJ, Astrup A. Twenty-four-hour energy expenditure: the role of body composition, thyroid status, sympathetic activity, and family membership. J Clin Endocrinol Metab. 1996;81(7):2670–4.PubMed
5.
Torring O, Tallstedt L, Wallin G, Lundell G, Ljunggren JG, Taube A, Thyroid Study Group, et al. Graves’ hyperthyroidism: treatment with antithyroid drugs, surgery, or radioiodine—a prospective, randomized study. J Clin Endocrinol Metab. 1996;81(8):2986–93.PubMed
6.
Porterfield JR Jr, Thompson GB, Farley DR, Grant CS, Richards ML. Evidence-based management of toxic multinodular goiter (Plummer’s Disease). World J Surg. 2008;32(7):1278–84.PubMedCrossRef
7.
Hegedus L. Treatment of Graves’ hyperthyroidism: evidence-based and emerging modalities. Endocrinol Metab Clin North Am. 2009;38(2):355–71, ix.
8.
Bahn Chair RS, Burch HB, Cooper DS, Garber JR, Greenlee MC, Klein I, et al. Hyperthyroidism and other causes of thyrotoxicosis: management guidelines of the American Thyroid Association and American Association of Clinical Endocrinologists. Thyroid. 2011;21(6):593–646.PubMedCrossRef
9.
Baskin HJ, Cobin RH, Duick DS, Gharib H, Guttler RB, Kaplan MM, et al. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the evaluation and treatment of hyperthyroidism and hypothyroidism. Endocr Pract. 2002;8(6):457–69.PubMed
10.
Liu J, Bargren A, Schaefer S, Chen H, Sippel RS. Total thyroidectomy: a safe and effective treatment for Graves’ disease. J Surg Res. 2011;168(1):1–4.PubMedCentralPubMedCrossRef
11.
Annerbo M, Stalberg P, Hellman P. Management of Grave’s disease is improved by total thyroidectomy. World J Surg. 2012;36(8):1943–6.PubMedCrossRef
12.
Wilhelm SM, McHenry CR. Total thyroidectomy is superior to subtotal thyroidectomy for management of Graves’ disease in the United States. World J Surg. 2010;34(6):1261–4.PubMedCrossRef
13.
Hoogwerf BJ, Nuttall FQ. Long-term weight regulation in treated hyperthyroid and hypothyroid subjects. Am J Med. 1984;76(6):963–70.PubMedCrossRef
14.
Abid M, Billington CJ, Nuttall FQ. Thyroid function and energy intake during weight gain following treatment of hyperthyroidism. J Am Coll Nutr. 1999;18(2):189–93.PubMedCrossRef
15.
De la Rosa RE, Hennessey JV, Tucci JR. A longitudinal study of changes in body mass index and total body composition after radioiodine treatment for thyrotoxicosis. Thyroid. 1997;7(3):401–5.PubMedCrossRef
16.
Greenlund LJ, Nair KS, Brennan MD. Changes in body composition in women following treatment of overt and subclinical hyperthyroidism. Endocr Pract. 2008;14(8):973–8.PubMedCrossRef
17.
Dale J, Daykin J, Holder R, Sheppard MC, Franklyn JA. Weight gain following treatment of hyperthyroidism. Clin Endocrinol (Oxf). 2001;55(2):233–9.PubMedCrossRef
18.
19.
Flegal KM, Carroll MD, Ogden CL, Curtin LR. Prevalence and trends in obesity among US adults, 1999–2008. JAMA. 2010;303(3):235–41.PubMedCrossRef
20.
Tenconi SM, Boni L, Colombo EM, Dionigi G, Rovera F, Cassinotti E. Laparoscopic cholecystectomy as day-surgery procedure: current indications and patients’ selection. Int J Surg. 2008;6 Suppl 1:S86–8.PubMedCrossRef
21.
Kitahara CM, Platz EA, Ladenson PW, Mondul AM, Menke A, Berrington de Gonzalez A. Body fatness and markers of thyroid function among U.S. men and women. PLoS One. 2012;7(4):e34979.PubMedCentralPubMedCrossRef
22.
23.
Zimmermann-Belsing T, Feldt-Rasmussen U. Obesity: the new worldwide epidemic threat to general health and our complete lack of effective treatment. Endocrinology. 2004;145(4):1501–2.PubMedCrossRef
24.
25.
26.
27.
Christakis NA, Fowler JH. The spread of obesity in a large social network over 32 years. N Engl J Med. 2007;357(4):370–9.PubMedCrossRef
28.
Dixon JB. Obesity and diabetes: the impact of bariatric surgery on type-2 diabetes. World J Surg. 2009;33(10):2014–21.PubMedCrossRef
29.
Lonn L, Stenlof K, Ottosson M, Lindroos AK, Nystrom E, Sjostrom L. Body weight and body composition changes after treatment of hyperthyroidism. J Clin Endocrinol Metab. 1998;83(12):4269–73.PubMed
30.
Jansson S, Berg G, Lindstedt G, Michanek A, Nystrom E. Overweight: a common problem among women treated for hyperthyroidism. Postgrad Med J. 1993;69(808):107–11.PubMedCentralPubMedCrossRef
31.
Svare A, Nilsen TI, Bjoro T, Asvold BO, Langhammer A. Serum TSH related to measures of body mass: longitudinal data from the HUNT Study, Norway. Clin Endocrinol (Oxf). 2011;74(6):769–75.CrossRef
32.
Fox CS, Pencina MJ, D’Agostino RB, Murabito JM, Seely EW, Pearce EN, et al. Relations of thyroid function to body weight: cross-sectional and longitudinal observations in a community-based sample. Arch Intern Med. 2008;168(6):587–92.PubMedCrossRef
33.
34.
Brennan AM, Mantzoros CS. Drug insight: the role of leptin in human physiology and pathophysiology–emerging clinical applications. Nat Clin Pract Endocrinol Metab. 2006;2(6):318–27.PubMedCrossRef
35.
Carleton RA, Lasater TM, Assaf AR, Feldman HA, McKinlay S. The Pawtucket Heart Health Program: community changes in cardiovascular risk factors and projected disease risk. Am J Public Health. 1995;85(6):777–85.PubMedCentralPubMedCrossRef
36.
Dubuc GR, Phinney SD, Stern JS, Havel PJ. Changes of serum leptin and endocrine and metabolic parameters after 7 days of energy restriction in men and women. Metabolism. 1998;47(4):429–34.PubMedCrossRef
37.
Hsieh CJ, Wang PW, Wang ST, Liu RT, Tung SC, Chien WY, et al. Serum leptin concentrations of patients with sequential thyroid function changes. Clin Endocrinol (Oxf). 2002;57(1):29–34.PubMedCrossRef
38.
Inui A, Asakawa A, Bowers CY, Mantovani G, Laviano A, Meguid MM, et al. Ghrelin, appetite, and gastric motility: the emerging role of the stomach as an endocrine organ. FASEB J. 2004;18(3):439–56.PubMedCrossRef
39.
Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H, Kangawa K. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature. 1999;402(6762):656–60.PubMedCrossRef
40.
Mozaffarian D, Hao T, Rimm EB, Willett WC, Hu FB. Changes in diet and lifestyle and long-term weight gain in women and men. N Engl J Med. 2011;364(25):2392–404.PubMedCentralPubMedCrossRef
41.
Rojdmark S, Calissendorff J, Danielsson O, Brismar K. Hunger-satiety signals in patients with Graves’ thyrotoxicosis before, during, and after long-term pharmacological treatment. Endocrine. 2005;27(1):55–61.PubMedCrossRef
42.
Hallgrimsson P, Nordenstrom E, Bergenfelz A, Almquist M. Hypocalcaemia after total thyroidectomy for Graves’ disease and for benign atoxic multinodular goitre. Langenbecks Arch Surg. 2012;397(7):1133–7.PubMedCrossRef
43.
Welch KC, McHenry CR. Total thyroidectomy: is morbidity higher for Graves’ disease than nontoxic goiter? J Surg Res. 2011;170(1):96–9.PubMedCrossRef
44.
Wong KP, Lang BH. Graves’ ophthalmopathy as an indication increased the risk of hypoparathyroidism after bilateral thyroidectomy. World J Surg. 2011;35(10):2212–8.PubMedCentralPubMedCrossRef
45.
Solomon B, Glinoer D, Lagasse R, Wartofsky L. Current trends in the management of Graves’ disease. J Clin Endocrinol Metab. 1990;70(6):1518–24.PubMedCrossRef
46.
Khadra M, Delbridge L, Reeve TS, Poole AG, Crummer P. Total thyroidectomy: its role in the management of thyroid disease. Aust N Z J Surg. 1992;62(2):91–5.PubMedCrossRef
Metadata
Title
Thyroidectomy as Primary Treatment Optimizes Body Mass Index in Patients with Hyperthyroidism
Authors
David F. Schneider, MD, MS
Ratnam Nookala, MBBS
Taylor J. Jaraczewski
Herbert Chen, MD
Carmen C. Solorzano, MD
Rebecca S. Sippel, MD
Publication date
01-07-2014
Publisher
Springer US
Published in
Annals of Surgical Oncology / Issue 7/2014
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-014-3542-8

Other articles of this Issue 7/2014

Annals of Surgical Oncology 7/2014 Go to the issue

Breast Oncology

Implant Breast Reconstruction and Radiation: A Multicenter Analysis of Long-Term Health-Related Quality of Life and Satisfaction

Hepatobiliary Tumors

Prognosis After Resection of Hepatitis B Virus-Related Hepatocellular Carcinoma Originating from Non-cirrhotic Liver

Breast Oncology

Prospective Study Evaluating Oncological Safety of Axillary Reverse Mapping

Bone and Soft Tissue Sarcomas

Sporadic Abdominal Wall Desmoid: Is it Time to Change Our First-Line Approach?

Gastrointestinal Oncology

Is Gastric Cancer Different in Korea and the United States? Impact of Tumor Location on Prognosis

Breast Oncology

Results of a Surgeon-Directed Quality Improvement Project on Breast Cancer Surgery Outcomes in South-Central Ontario